This post is pure speculation, but-
The $15 mil dep was only for UNIS not to negotiate with any other, till the end of month.
What if- a competitor of Amgen, said to UNIS- We will give you $100 mil non refundable, for the right to negotiate, for a month.
Why would they do this?
Now they have an understanding of the scope of the Amgen deal and how it may affect there operations.
In particular, its the small volumes wearables, I am thinking about and the exclusive perpetual license for Amgen.
AbbVie has been negotiating for the Unifinese combined with the Lisa auto injector, which has to be combined with AbbVie drug and another drug that Abbvie has to pay $130 mil royalty for each drug, and they still end up with an syringe injection type drug, that potentially hurts, and has to be self injected, and has privacy and convenience issues, as against a small wearable that can slowly inject over time, is warmed by the body is private and convenient.
It's not just AbbVie, Sanofi has access to all large wearables, but the small volume wearable may not be part of the deal.
There could be more going on.
You don't have to abuse me, but if you want to think about it, you can.
If it's too hard just don't worry, and wait
All will be revealed
All JMO
- Forums
- ASX - By Stock
- UNS
- The Deal
The Deal, page-24
-
-
- There are more pages in this discussion • 103 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add UNS (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online